Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

Published:2018-08-31 Issue:4 Volume:1 Page:e00036
ISSN:2398-9238
Container-title:Endocrinology, Diabetes & Metabolism
language:en
Short-container-title:Endocrinol Diab Metab

Author:

Persson Frederik¹,Bodegard Johan²^ORCID,Lahtela Jorma T.³,Nyström Thomas⁴,Jørgensen Marit E.¹⁵,Jensen Majken Linneman¹,Gulseth Hanne L.⁶,Thuresson Marcus⁷,Hoti Fabian⁸,Nathanson David⁴,Norhammar Anna⁹¹⁰,Birkeland Kåre I.⁶¹¹^ORCID,Eriksson Johan G.¹²,Eriksson Jan W.¹³^ORCID

Affiliation:

1. Steno Diabetes Center Copenhagen; Gentofte Denmark

2. AstraZeneca Nordic-Baltic; Oslo Norway

3. Tampere University Hospital; Tampere Finland

4. Department of Clinical Science and Education; Södersjukhuset, Karolinska Institutet; Stockholm Sweden

5. National Institute of Public Health; Southern Denmark University; Odense Denmark

6. Oslo University Hospital; Oslo Norway

7. Statisticon AB; Uppsala Sweden

8. StatFinn & EPID Research; Espoo Finland

9. Karolinska Institutet; Stockholm Sweden

10. Karolinska Institutet; Capio S:t Görans Hospital; Stockholm Sweden

11. University of Oslo; Oslo Norway

12. Department of General Practice and Primary Health Care; University of Helsinki and Helsinki University Hospital; Helsinki Finland

13. Department of Medical Sciences; Uppsala University; Uppsala Sweden

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/edm2.36/fullpdf

Reference38 articles.

1. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

2. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis;Birkeland;Lancet Diabetes Endocrinol,2017

3. Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL Study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors);Kosiborod;Circulation,2017

4. Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes;Marso;N Engl J Med,2016

5. Liraglutide and cardiovascular outcomes in Type 2 Diabetes;Marso;N Engl J Med,2016

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Second-line pharmacotherapy intensification after metformin monotherapy in type 2 diabetes: a nationwide register study from Finland during 2011–2022;BMC Health Services Research;2024-08-19

2. Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study;eClinicalMedicine;2024-07

3. The associations of sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors as add‐on to metformin with fracture risk in patients with type 2 diabetes mellitus;Diabetes, Obesity and Metabolism;2023-07-28

4. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study;Cardiovascular Diabetology;2023-06-29

5. Biochemical profiling, pharmacological management and clinical outcomes in type 2 diabetes in Danish primary care from 2001 to 2015;Primary Care Diabetes;2022-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3